Hypoallergenic Infant Formulas
Abstract
The
Abbreviation
IgE, immunoglobulin E.
Symptoms
of food protein allergy include those commonly associated with immunoglobulin E
(IgE)-associated reactions, such as angioedema, urticaria, wheezing, rhinitis,
vomiting, eczema, and anaphylaxis.1 Non-IgE-associated,
immunologically mediated conditions have also been associated with the
ingestion of cow's milk, soy, and other dietary proteins in infant feedings.
These disorders include pulmonary hemosiderosis,2 malabsorption with
villous atrophy,3 eosinophilic proctocolitis,4
enterocolitis,5 and esophagitis.6 Finally, some infants
may experience extreme irritability or colic as the only symptom of food
protein allergy.7 The prevalence in infancy of milk protein allergy
is low — 2 percent to 3 percent.8-10 Thus, the use of
hypoallergenic-labeled infant formulas, which cost as much as three times more
than standard formulas, should be limited to infants with well-defined clinical
indications. Adverse reactions to cow's milk associated with other conditions
such as phenylketonuria and lactose intolerance may also be alleviated by the
use of alternative formulas, although not necessarily those intended to treat
infants with protein allergy.
Formula
Development and Labeling
Before
new potential hypoallergenic formulas are tested in trials using human infants,
comprehensive preclinical testing must be conducted to examine for toxicity and
suitability to maintain a positive nitrogen balance and to attempt to predict
whether infants allergic to cow's milk will react adversely to them. This
testing should include efforts to determine the molecular weight profile of
residual peptides, the amount of immunologically recognizable material present,
and the ability of the product to sensitize or provoke reactions in animal
models of allergenicity.11-14
To
establish the risk of hypersensitivity in infants, carefully conducted
preclinical studies must be performed that demonstrate a formula may be
hypoallergenic. The formula needs to be tested in infants with hypersensitivity
to cow's milk or cow's milk-based formula and the findings verified by properly
conducted elimination-challenge tests.15 These tests should, at a
minimum, ensure with 95 percent confidence that 90 percent of infants with
documented cow's milk allergy will not react with defined symptoms to the
formula under double-blind, placebo-controlled conditions.16 Such
formulas can be labeled hypoallergenic. If the formula being tested is not
derived from cow's milk proteins, the formula must also be evaluated in infants
or children with documented allergy to the protein from which the formula was
derived. It is also recommended that after a successful double-blind challenge,
the clinical testing should include an open challenge using an objective
scoring system to document allergic symptoms during a period of seven days.16
This is particularly important to detect late-onset
reactions to the formula.17
Any
formula with residual peptides may provoke reactions in infants allergic to
cow's milk.17,18 Extensively hydrolyzed proteins derived from cow's
milk, in which most of the nitrogen is in the form of free amino acids and
peptides <1500 kDa, have been used in formulas for >50 years for infants
with severe inflammatory bowel diseases or cow's milk allergy. These formulas,
as well as the newer free amino acid-based formulas, have been subjected to extensive
clinical testing and meet the standard for hypoallergenicity.19-21
Hypoallergenic
formulas are intended for use by infants with existing allergic symptoms.
Recently formulas have also been promoted to prevent the development of allergy
in infants at high risk for developing allergic symptoms. The ability to
determine which infants are at high risk is imperfect, although many markers,
including elevated levels of cord blood IgE and serum IgE in infancy and an
atopic family history, have been identified.22 Because a family
history of allergy is at least as sensitive and specific as any other marker,23 infants from families with a history of
allergy should serve as the study participants in clinical testing of formulas
that claim the ability to prevent allergy from developing. These infants should
be fed the formula exclusively from birth for at least six months under the
conditions of a controlled, randomized study and observed for at least 12
additional months. Allergic symptoms during the period of observation should be
documented with a validated clinical scoring system and allergic symptoms
verified by double-blind, placebo-controlled testing. When compared with
infants fed a standard cow's milk formula, infants fed formulas that claim to
prevent or delay allergy should have a statistically significant lower
prevalence of allergy at the end of the observation period.16
Clinical
Practice Treatment
Breast
milk is the optimal sole source of nutrition for healthy infants for the first
six months of life. Breastfeeding should be continued for the first 12 months
of life or longer. Although the incidence of food allergy is very low in
breastfed infants compared with formula-fed infants, rare cases of anaphylaxis
to cow's milk proteins have been reported in those breastfed as well as more
frequent cases of cow's milk-induced proctocolitis.24-26 The
pathophysiology of these reactions in the breastfed infant is not
well-understood. However, immunologically recognizable proteins from the
maternal diet can be found in breast milk.27,28
Elimination
of cow's milk, eggs, fish, peanuts and tree nuts and other foods from the
maternal diet may lead to resolution of allergic symptoms in the nursing
infant. For those infants whose symptoms do not improve or whose mothers are
unable to participate in a very restricted diet regimen and for formula-fed
infants with cow's milk allergy, alternative formulas can be used to relieve
the symptoms.
In
infants allergic to cow's milk, milk from goats and other animals29
or formulas containing large amounts of intact animal protein are inappropriate
substitutes for breast milk or cow's milk-based infant formulas. Soy formulas
have a long history as alternative formulas in infants who are allergic. Eight
to 14 percent of infants with symptoms of IgE-associated cow's milk allergy
will also react adversely to soy,30 but
reports of anaphylaxis to soy are extremely rare. Those infants allergic to
cow's milk and who do not have an adverse reaction at the start of feeding on a
soy formula tolerate it very well.31 Thus, although soy formulas are
not hypoallergenic, they can be fed to infants with IgE-associated symptoms of
milk allergy, particularly after the age of six months.29 There is a
significantly higher prevalence of concomitant reactions between cow's milk and
soy proteins (25 percent-60 percent) among those infants with proctocolitis and
enterocolitis32 and therefore soy is not recommended for the
treatment of infants with these non-IgE-associated syndromes.31
Formulas
based on partially hydrolyzed cow's milk proteins (1000-100,000 times higher
concentrations of intact cow's milk proteins compared with extensively
hydrolyzed protein) have provoked significant reactions in a high percentage of
infants allergic to cow's milk33,34 and are not intended to be used
to treat cow's milk allergy. Extensively hydrolyzed formulas have also provoked
allergic reactions in infants allergic to cow's milk,17,18
but at least 90 percent of these infants tolerate extensively hydrolyzed
formulas as well as the more recently introduced free amino acid-based infant
formulas. Although the majority of infants with colic will not respond to a
hypoallergenic formula, those with severe colic may benefit from a one- to
two-week trial of a hypoallergenic formula.7
Prophylaxis
Recent
studies, one a randomized and prospectively controlled study of preterm infants
followed up for 18 months35 and a second prospective nonrandomized
and uncontrolled study of full-term infants followed up for 17 years,36
have demonstrated that breastfeeding exclusively for at least six months
reduces the risk of later respiratory allergic symptoms and eczema. Although
many of the studies that have examined the ability of breastfeeding to delay or
prevent allergic disease have significant methodologic shortcomings,22,37 the total of these studies suggests that
breastfeeding exclusively has a protective effect, at least in high-risk
infants and particularly if it is combined with maternal avoidance of cow's
milk, egg, fish, peanuts and tree nuts during lactation.
More
definitive prospective studies of the use of alternative formulas for allergy
prophylaxis in high-risk infants are needed. However, the prospective studies
available that utilized blinded food challenges to confirm allergic symptoms
suggest that asymptomatic formula-fed infants at high risk for allergy given
alternatives to cow's milk formulas may have a lower future risk of allergic
disease or delayed onset of allergic symptoms. In one recently reported study,
infants at high risk for allergy fed an extensively hydrolyzed formula or
breastfed infants whose mothers avoided cow's milk, egg, and peanuts and did
not introduce these foods into their infants' diets had a reduced prevalence of
all allergic disorders at one year compared with the control group fed a
standard cow's milk formula.38 However, at seven years of age there
were no differences in allergic respiratory symptoms between the two groups.
A
recent meta-analysis of all prospective controlled trials of a partially hydrolyzed
formula showed a significant prophylactic effect of the partially hydrolyzed
formula on the development of atopic symptoms at 60 months of age.39
The studies analyzed did not all include confirmation of allergic symptoms by
blinded challenge. In the only prospective study of allergy prophylaxis in
high-risk infants that compared a partially and extensively hydrolyzed formula,
only the extensively hydrolyzed formula prevented the development of allergy
during the first 18 months of life in high-risk infants.40 The other comparison groups in this study were fed a cow's
milk-based formula or were breastfed exclusively for more than nine months.
Solid feedings were delayed until four months of age, and eggs, cow's milk and
fish were eliminated from the mothers' diets and their introduction delayed in
their infants' diets until after the first year of life. Randomized prospective
studies of soy protein-based formulas have not shown a preventive effect of
these formulas on the development of allergy in high-risk infants.41,42 No published studies have examined the
effectiveness of free amino acid-based formulas on allergy prevention in
high-risk infants.
Conclusion
Hypoallergenic
formulas, like all formulas intended for infant feeding, must demonstrate
nutritional suitability to support infant growth and development. To be labeled
hypoallergenic, these formulas, after appropriate preclinical testing, must
demonstrate in clinical studies that they do not provoke reactions in 90
percent of infants or children with confirmed cow's milk allergy with 95
percent confidence when given in prospective randomized, double-blind,
placebo-controlled trials.
Extensively
hydrolyzed and free amino acid-based formulas have been subjected to such
studies and are hypoallergenic. Currently available, partially hydrolyzed
formulas are not hypoallergenic. Carefully conducted randomized controlled
studies in infants from families with a history of allergy must be performed to
support a formula claim for allergy prevention. Allergic responses must be
established prospectively, evaluated with validated scoring systems, and
confirmed by double-blind, placebo-controlled challenge. These studies should
continue for at least 18 months and preferably for 60 to 72 months or longer
where possible.
Recommendations
1. Breast milk is an optimal
source of nutrition for infants through the first year of life or longer. Those
breastfeeding infants who develop symptoms of food allergy may benefit from:
a.
maternal
restriction of cow's milk, egg, fish, peanuts and tree nuts and if this is
unsuccessful,
b.
use of a hypoallergenic (extensively hydrolyzed or if
allergic symptoms persist, a free amino acid-based formula) as an alternative
to breastfeeding. Those infants with IgE-associated symptoms of allergy may
benefit from a soy formula, either as the initial treatment or instituted after
six months of age after the use of a hypoallergenic formula. The prevalence of
concomitant is not as great between soy and cow's milk in these infants compared
with those with non-IgE-associated syndromes such as enterocolitis,
proctocolitis, malabsorption syndrome, or esophagitis. Benefits should be seen
within two to four weeks and the formula continued until the infant is one year
of age or older.
2. Formula-fed infants with
confirmed cow's milk allergy may benefit from the use of a hypoallergenic or
soy formula as described for the breastfed infant.
3. Infants at high risk for
developing allergy, identified by a strong (biparental; parent, and sibling)
family history of allergy may benefit from exclusive breastfeeding or a
hypoallergenic formula or possibly a partial hydrolysate formula. Conclusive
studies are not yet available to permit definitive recommendations. However,
the following recommendations seem reasonable at this time:
a.
Breastfeeding
mothers should continue breastfeeding for the first year of life or longer.
During this time, for infants at risk, hypoallergenic formulas can be used to
supplement breastfeeding. Mothers should eliminate peanuts and tree nuts (eg,
almonds, walnuts, etc) and consider eliminating eggs, cow's milk, fish, and
perhaps other foods from their diets while nursing. Solid foods should not be
introduced into the diet of high-risk infants until six months of age, with
dairy products delayed until one year, eggs until two years, and peanuts, nuts,
and fish until three years of age.
b.
No
maternal dietary restrictions during pregnancy are necessary with the possible
exception of excluding peanuts;
4. Breastfeeding mothers on a
restricted diet should consider the use of supplemental minerals (calcium) and
vitamins.
Committee on Nutrition, 1999-2000
Susan S. Baker, MD, PhD, Chairperson
William J. Cochran, MD
Frank R. Greer, MD
Melvin B. Heyman, MD
Marc S. Jacobson, MD
Tom Jaksic, MD, PhD
Nancy F. Krebs, MD
Liaison
Representatives
Alice E. Smith, MS, RD
American Dietetic Association
Doris E. Yuen, MD, PhD
Canadian Paediatric Society
William Dietz, MD, PhD
Centers for Disease Control and Prevention
Elizabeth Yetley, PhD
Food and Drug Administration
Suzanne S. Harris, PhD
International Life Sciences Institute
Ann Prendergast, RD, MPH
Maternal and Child Health Bureau
Gilman Grave, MD
National Institute of Child Health and Human Development
Van S. Hubbard, MD, PhD
National Institute of Diabetes and Digestive and Kidney
Diseases
Donna Blum-Kemelor, MS, RD
US Department of Agriculture
Section Liaisons
Ronald M. Lauer, MD
Section on Cardiology
Scott C. Denne, MD
Section on Perinatal Pediatrics
Consultant
Ronald Kleinman, MD
Staff
Pamela Kanda, MPH
Acknowledgement
The technical assistance of and review by the Section on Allergy and Immunology
Executive Committee is appreciated.
References
Pediatrics, Volume 106, Number 2, August 2000, p 346-349
The recommendations in
this statement do not indicate an exclusive course of treatment or serve as a
standard of medical care. Variations, taking into account individual
circumstances, may be appropriate.
© 2000 American
No part of this statement may be reproduced in any form or by any means without
prior written permission from the